The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacokinetics and pharmacodynamics of the dual syk/jak inhibitor PRT062070 (cerdulatinib) in patients with advanced B-cell malignancies.
Ian Flinn
Research Funding - Portola Pharmaceuticals
Manish R. Patel
No relevant relationships to disclose
Nina D. Wagner-Johnston
No relevant relationships to disclose
Anjali Pandey
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals
Greg Coffey
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals
Janet Leeds
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals
Stanley Hollenbach
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals
Sandra Russell
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals
Dale Baker
Employment or Leadership Position - Portola Pharmaceuticals
Consultant or Advisory Role - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals
Gallia G. Levy
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals
John T Curnutte
Employment or Leadership Position - Portola Pharmaceuticals
Stock Ownership - Portola Pharmaceuticals